Search published articles


Showing 3 results for Genetics

Javad Tavakkoly Bazzaz, Vera Pravica, Andrew Jm Boulton, Ian V Hutchinson,
Volume 4, Issue 1 (7-2004)
Abstract

Background: Due to homeostatic and regulatory potentials of nitric oxide (NO) in vascular physiology, regulatory systems that determine NO bio-synthesis and bioavailability have been the subject of extensive research in molecular medicine. In the field of vascular system pathophysiology, endothelial nitric oxide synthase (eNOS) which is the major producer and regulator of NO in vascular tissues has received the most attention. Impairment of NO bioavailability (NO quenching) is a common feature in poorly controlled diabetics due to increased catabolism and decreased production of NO. Such impairment in severe forms could end to vasodilation breakdown in peripheral tissues (mainly in skeletal muscles) and defective regional blood flow, that in turn disturb insulin-dependent glucose uptake ensuing insulin resistance state.
Methods: The phenotypic impact of an eNOS gene polymorphism at position 786*C/T (that its functionality has been revealed already) on genetic propensity to diabetic retinopathy is evaluated in a British-Caucasian population with type 1 diabetes (T1DM).
Results: In contrast to genotypes, there was a significant difference in distribution of allele frequencies between T1DM patients (n= 249) and healthy controls (n= 104) (p= 0/036), that may imply eNOS and/or NO involvement in development of T1DM. Most notably a significant difference also was evident in allele frequency between retinopaths (n= 134) and healthy controls (p= 0/02). No significant difference was detected when the genotype/allele frequencies were compared between retinopaths (n= 134) and non-retinopaths diabetics (n= 115) (p=NS).
Conclusion: Our data is compatible with previous studies which demonstrated that allele C of eNOS 786*C/T polymorphism is associated with increased HbA1c levels. By emphasizing the phenotypic and prognostic value of the abovementioned polymorphism, our data calls for further investigations to find out whether this polymorphism can be employed as a genetic marker in clinical medicine to recognize high-risk diabetics at the time of diabetes onset/diagnosis.
Javad Tavakkoly Bazzaz, Vera Pravica, Andrew Jm Boulton, Ian V Hutchinson,
Volume 4, Issue 1 (7-2004)
Abstract

Background: Type 1 diabetes (T1DM) is an organ specific auto-immune disease, which is resulted by selective destruction of  islet cells. Insulitis as the initial event prior to T1DM development is featured mainly by lymphocytic infiltration, that may recede frequently leading to healthy state (benign insulitis). Among the issues that govern which of these outcome lie ahead in insulitis are the genetic background of the host and also the immunological circumstances in  islets' micro-environment.
Methods: As a "case-control association study" the impact of a polymorphism within TNF- gene at position -308*G/A on genetic susceptibility to T1DM is analyzed in a British-Caucasian population (248 cases and 118 healthy controls).
Results: The distribution of genotype/allele frequencies between patients and controls did not reflect significant differences (p= NS).
Conclusion: Since the crucial role of TNF- in development of T1DM is well established, our data may confer that the examined polymorphic marker does not have functional effects on TNF- gene expression, influencing the local or systemic level of this pro-inflammatory cytokine. However, in addition to addressing the uncertainties in "genotype-phenoype" correlations in complex diseases (i.e. T1DM), the negative results of our study also may instead draw attention to the potential impacts of post-transcriptional regulatory mechanisms relative to gene structural-based regulatory systems.
Negar Sarhangi, Mandana Hasanzad, Fatemeh Rouhollah, Shekoufeh Nikfar, Farshad Sharifi, Negar Niknam,
Volume 25, Issue 2 (7-2025)
Abstract

 
Background: Pharmacogenomics (PGx), as a growing field of personalized medicine, aims to optimize the efficacy and safety of medications by studying the association between germline genetic variations and drug responses. The present cross-sectional study aims to evaluate the allele frequency of the NUDT15 genetic variant in the Iranian population to provide insights into personalized treatment decisions in the Iranian population.
Methods: A representative sample set of 1142 unrelated healthy Iranian individuals aged 18 and older genotyped using the Infinium Global Screening Array-24 BeadChip.
Results: We identified a pharmacogenetic variant with minor allele frequency (MAF) ≥1% among the present studied population which may explain the substantial variability in drug response phenotypes among different populations
Conclusion: The results of our study revealed significant genetic variation among Iranian populations that could significantly influence clinical decision-making. This study shows the frequency pattern of the effective variant of NUDT15 in determining the phenotype in Iranian population.
 

Page 1 from 1     

© 2026 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by: Yektaweb